8 completed, 1 unknown. 9 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 8, Unknown 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Extensively Drug-Resistant Tuberculosis: new trials by email Literature Review of Extensively Drug-Resistant Tuberculosis trials Research Report on Extensively Drug-Resistant Tuberculosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Economic Evaluation of New MDR TB Regimens Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 73 | 2020-10-20 | 2024-04-22 |
| Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) Bedaquiline 100 MG, Delamanid 50 MG Oral Tablet, Clofazimine 100 MG Oral Capsule - Tuberculosis, Multidrug-Resistant, Tuberculosis | Phase 3 | Completed | Médecins Sans Frontières, France | 323 | 2020-04-06 | 2025-02-10 |
| Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care Bedaquiline Oral Tablet, Linezolid Oral Tablet, Delamanid in Oral Dosage Form - Tuberculosis, Pre-XDR-TB | Phase 3 | Completed | Wits Health Consortium (Pty) Ltd | 402 | 2019-08-22 | 2024-08-28 |
| PRACTECAL-PKPD Sub Study Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Unknown | Medecins Sans Frontieres, Netherlands | 240 | 2019-08-06 | 2021-05-14 |
| Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Pretomanid, Linezolid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 3 | Completed | Global Alliance for TB Drug Development | 181 | 2017-11-21 | 2023-06-29 |
| Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Bedaquiline, Pretomanid, Moxifloxacin - Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 552 | 2017-01-01 | 2024-05-01 |
| An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis Linezolid, Bedaquiline, Levofloxacin - Tuberculosis, Multidrug Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | University of Cape Town | 154 | 2015-11-12 | 2021-09-29 |
| A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB Bedaquiline, PA-824, Linezolid - Pulmonary Tuberculosis | Phase 3 | Completed | Global Alliance for TB Drug Development | 109 | 2015-03-01 | 2025-09-08 |
| Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV Immunoxel, Placebo - Tuberculosis, HIV | Phase 3 | Completed | Lisichansk Regional Tuberculosis Dispensary | 269 | 2010-01-01 | 2015-05-20 |
Tuberculosis, Multidrug-Resistant (9) · Tuberculosis (6) · Tuberculosis, Pulmonary (6) · Bacterial Infections (1) · Gram-Positive Bacterial Infections (1) · Mycobacterium Infections (1)
Actinomycetales Infections (9) · Bacterial Infections and Mycoses (9) · Infections (9) · Bacterial Infections (8) · Gram-Positive Bacterial Infections (8) · Mycobacterium Infections (8) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Tuberculosis (3)
Linezolid (8) · bedaquiline (8) · Clofazimine (5) · pretomanid (5) · Moxifloxacin (4) · Levofloxacin (2) · OPC-67683 (2) · Dosage Forms (1) · Ethionamide (1) · Isoniazid (1) · Kanamycin (1) · Pyrazinamide (1) · Tablets (1) · terizidone (1)
Medecins Sans Frontieres, Netherlands (3) · Global Alliance for TB Drug Development (2) · Lisichansk Regional Tuberculosis Dispensary (1) · Médecins Sans Frontières, France (1) · University of Cape Town (1) · Wits Health Consortium (Pty) Ltd (1)
South Africa (7) · Belarus (3) · Uzbekistan (2) · Georgia (1) · India (1) · Kazakhstan (1) · Lesotho (1) · Moldova (1) · Mongolia (1) · Pakistan (1) · Peru (1) · Russia (1) · Ukraine (1) · Vietnam (1)
Bern Nyang'wa, MB BS, MPH (1) · Bern-Thomas Nyang'wa, MD (1) · Carole Mitnick, Sc.D (1) · Francesca Conradie (1) · Francesca Conradie, MD (1) · Francesca M Conradie (1) · Keertan Dheda, MBChB (1) · Lorenzo Guglielmetti, MD (1) · Morounfolu Olugbosi, MD (1) · Sedona Sweeny (1)
PMID 22397570, PMID 22401633, PMID 27868466, PMID 31932382, PMID 32130813, PMID 34489274, PMID 34604901, PMID 35175905, PMID 35698158, PMID 36053506, PMID 36546625, PMID 36804834, PMID 37980911, PMID 38037119, PMID 38842323, PMID 40683298, PMID 41917253, PMID 42270675, PMID 42341301, PMID 42429813